Hyderabad, India; 29th July 2020: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of antiretroviral drugs, today announces the launch of generic Favipiravir in India under the brand name ‘Favivir.’ Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid 19 patient population, which usually sustains mild to moderate symptoms.
Hetero’s Favivir is priced at Rs. 59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available from today at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.
Backed by strong vertical integration capabilities, the drug is being manufactured at our world-class formulation facility in India, which has been approved by stringent global regulatory authorities such as USFDA and the EU, among others.
The prototypes of the packs highlighting their security features was the talking point among the visitors as it effectively showcased our efforts in preventing the menace of counterfeit drugs.
The presence of Mr Murali Krishna Reddy Director- Marketing, Emerging markets had a motivating effect on Hetero Biopharma marketing team. Headed by Dr. A.V. Jayapala Reddy, AVP and Global head - Biologics Business, the Hetero Biopharma team comprising of Dr. Vikram Kumar Shetty GM - Medico marketing and Clinical affairs, Mr. Y. Ramesh Reddy - Marketing Manager, Mr. A. Vinod, Manager - Marketing, Mr. Shanker Maharaju - Manager, Mr. D. Sharath Asst. Manager- Marketing, and Mr. T. Sai Pavan Kumar - Marketing Officer, contributed to this event’s huge success.